Bladder Botox denied as non-formulary by Humana?

Humana's specific coverage criteria for bladder botox are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Bladder Botox as Non-Formulary — and Why You Can Appeal

OnabotulinumtoxinA (Botox) for bladder conditions may appear on Humana's formulary only on a restricted tier — requiring prior authorization or step therapy as a condition of coverage — or it may not appear on some Humana plan formularies at all. A non-formulary denial means either that the drug is not listed on your specific plan's formulary, or that it is listed at a tier that requires additional criteria to be met before coverage is approved. The key distinction is whether a formulary exception is available and whether the clinical record supports that exception. Formulary-exception appeals are a well-established pathway and succeed regularly when medical necessity is clearly documented.

## Federal Appeal Framework

• Formulary exception request: Before filing a formal appeal, confirm whether your plan allows a formulary exception request, which is a separate administrative pathway to obtain coverage for a non-formulary drug. Many Humana plans permit this when the prescriber certifies that formulary alternatives are clinically inappropriate for the patient.
• Internal appeal (ERISA §503 / ACA §2719): File within 180 days of the denial. If a formulary exception was denied, the internal appeal reviews that determination under a full-and-fair standard.
• External review (ACA §2719): Available after internal exhaustion, typically within approximately four months of the final internal denial. The IRO evaluates whether the formulary exception criteria were correctly applied.
• Expedited review: Available if the patient's condition creates a health urgency.

## Documentation to Gather

1. Formulary alternative failure record: Identify each formulary-preferred alternative for overactive bladder or neurogenic bladder that Humana would cover, and document why each was tried and failed, or is clinically inappropriate for this patient. This is the core of a formulary exception appeal. 2. Prescriber exception letter: A letter from the treating urologist or urogynecologist explaining that formulary alternatives have been inadequate or are contraindicated, that onabotulinumtoxinA is medically necessary for this specific patient, and referencing the applicable guideline organization (e.g., AUA). 3. Diagnosis and severity documentation: Clinical notes, urodynamic results if available, and voiding diary records establishing the diagnosis and the inadequacy of prior treatment. 4. FDA labeling: The current FDA-approved prescribing label for onabotulinumtoxinA demonstrating the approved bladder indication and the patient's qualifying criteria. 5. Humana formulary exception criteria: Download the current Humana formulary exception policy and address every criterion in the prescriber letter and supporting documentation.

## Criteria-Mapping Structure

| Formulary Exception Criterion (from Humana policy) | Patient-Specific Evidence | |---|---| | Formulary alternative(s) are clinically contraindicated or have failed | Record of each alternative: dates, response, prescriber assessment | | Non-formulary drug is medically necessary for this patient | Prescriber exception letter with clinical rationale | | FDA-approved for the relevant indication | FDA label — approved indication matches documented diagnosis | | [Each additional exception criterion] | [Chart reference with date, provider, and finding] |

Confirm the exact formulary status and exception requirements from your specific Humana plan's current formulary document and the current Humana coverage policy for onabotulinumtoxinA — formulary tiers and exception criteria vary by plan and are updated annually.